Thrombotic microangiopathy (TMA) is a clinicopathologic diagnosis characterized by thrombocytopenia, microangiopathic hemolytic anemia, and microthrombi. Several pathogenetic mechanisms have been proposed, we focus on the potential contribution of genetic mutation in Complement-Mediated TMA (CM-TMA). A 21-year-old female presented at our hospital in the context of an unsupervised pregnancy and a presumptive diagnosis of pre-eclampsia was given. Laboratory studies revealed microangiopathic hemolytic anemia and kidney insufficiency that continue to worse after delivery. Plasmapheresis and eculizumab were provided with initial analytic stabilization followed by progressive improvement. She was dialysis dependent for one month. The genetic study revealed a new mutation, previously undescribed likely pathogenic variant, associated to CM-TMA. She continues eculizumab treatment and the investigation of TMA. This is an interesting case since new mutations are not that difficult to find, but there pathogenetic role is challenging to establish.
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2022
SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.
See moreSNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.
See more